Paul Tudor Jones Anavex Life Sciences Corp. Transaction History

Tudor Investment Corp Et Al

  • $15.5 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$7.65 - $14.43 $262,777 - $495,670
34,350 New
34,350 $318,000
Q3 2021

Nov 15, 2021
SELL
$16.82 - $25.75 $563,150 - $862,135
-33,481 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$10.16 - $28.86 $340,166 - $966,261
33,481 New
33,481 $765,000

Others Institutions Holding AVXL

# of Institutions
159
Shares Held
31.6M
Call Options Held
910K
Put Options Held
1.35M
View Full List

About ANAVEX LIFE SCIENCES CORP.

AVXL Quotes by TradingView
  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $352M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email